AAPL299.23+1.22 (+0.41%) ▲|ABBV229.90+13.41 (+6.19%) ▲|ABT88.22-0.19 (-0.21%) ▼|ACN119.17-8.82 (-6.89%) ▼|ADBE192.21-2.95 (-1.51%) ▼|AMAT622.55+5.44 (+0.88%) ▲|AMD545.39+8.02 (+1.49%) ▲|AMGN343.49+5.89 (+1.74%) ▲|AMT176.87+0.82 (+0.47%) ▲|AMZN234.41-9.99 (-4.09%) ▼|AVGO394.63-16.72 (-4.06%) ▼|AXP336.49-1.51 (-0.45%) ▼|BA220.85-1.87 (-0.84%) ▼|BAC57.32+1.12 (+1.98%) ▲|BKNG167.98-3.80 (-2.21%) ▼|BLK1,046.72-3.38 (-0.32%) ▼|BMY54.41+0.41 (+0.75%) ▲|BNY145.86+2.23 (+1.55%) ▲|BRK-B489.03-0.43 (-0.09%) ▼|C145.35+2.29 (+1.60%) ▲|CAT1,017.74+31.92 (+3.24%) ▲|CL89.69+0.21 (+0.23%) ▲|CMCSA22.40-0.04 (-0.16%) ▼|COF200.90-0.64 (-0.32%) ▼|COP109.38+1.64 (+1.52%) ▲|COST948.42-3.03 (-0.32%) ▼|CRM149.11-2.67 (-1.76%) ▼|CSCO121.19+1.65 (+1.38%) ▲|CVS101.85+3.53 (+3.59%) ▲|CVX175.00+1.37 (+0.79%) ▲|DE596.83+7.59 (+1.29%) ▲|DHR177.81+0.64 (+0.36%) ▲|DIS101.91-1.99 (-1.91%) ▼|DUK124.26+0.40 (+0.32%) ▲|EMR149.71-0.95 (-0.63%) ▼|FDX327.69+2.71 (+0.83%) ▲|GD343.06-6.95 (-1.99%) ▼|GE357.43-0.21 (-0.06%) ▼|GEV1,126.04+16.31 (+1.47%) ▲|GILD124.53+0.77 (+0.62%) ▲|GM80.88+1.59 (+2.01%) ▲|GOOG347.18-20.28 (-5.52%) ▼|GOOGL347.82-20.21 (-5.49%) ▼|GS1,098.72+2.16 (+0.20%) ▲|HD326.72-7.56 (-2.26%) ▼|HON228.36-0.66 (-0.29%) ▼|IBM246.50-2.60 (-1.04%) ▼|INTC140.81+6.82 (+5.09%) ▲|INTU256.53-10.47 (-3.92%) ▼|ISRG401.95-4.83 (-1.19%) ▼|JNJ230.40+2.01 (+0.88%) ▲|JPM331.90+6.68 (+2.05%) ▲|KO79.84+0.45 (+0.57%) ▲|LIN514.18+2.03 (+0.40%) ▲|LLY1,104.38+5.81 (+0.53%) ▲|LMT492.33-18.62 (-3.64%) ▼|LOW214.13-8.07 (-3.63%) ▼|LRCX395.18+6.14 (+1.58%) ▲|MA483.72-6.07 (-1.24%) ▼|MCD270.80-7.82 (-2.81%) ▼|MDLZ59.85-0.27 (-0.45%) ▼|MDT79.17-0.17 (-0.21%) ▼|META565.20-12.02 (-2.08%) ▼|MMM162.45+1.85 (+1.15%) ▲|MO69.65+0.53 (+0.76%) ▲|MRK114.75+0.88 (+0.77%) ▲|MS227.19+4.02 (+1.80%) ▲|MSFT370.13-9.27 (-2.44%) ▼|MU1,194.66+60.67 (+5.35%) ▲|NEE86.60-0.16 (-0.18%) ▼|NFLX72.86-4.52 (-5.84%) ▼|NKE43.21-2.00 (-4.41%) ▼|NOW92.05-2.99 (-3.15%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.26-9.04 (-4.90%) ▼|PEP140.70-1.33 (-0.93%) ▼|PFE25.01-0.21 (-0.81%) ▼|PG148.80-1.58 (-1.05%) ▼|PLTR119.62-8.86 (-6.89%) ▼|PM173.53-4.87 (-2.73%) ▼|QCOM222.21-3.90 (-1.72%) ▼|RTX182.46-3.14 (-1.69%) ▼|SBUX100.00-0.65 (-0.65%) ▼|SCHW92.03+0.33 (+0.35%) ▲|SO93.86+0.77 (+0.82%) ▲|SPG213.67+2.34 (+1.11%) ▲|T22.17+0.16 (+0.70%) ▲|TMO461.89-2.72 (-0.59%) ▼|TMUS181.05-0.62 (-0.34%) ▼|TSLA405.86+5.37 (+1.34%) ▲|TXN328.55+5.69 (+1.76%) ▲|UBER71.74+0.10 (+0.14%) ▲|UNH408.36+7.40 (+1.84%) ▲|UNP259.79+2.91 (+1.13%) ▲|UPS107.50+2.64 (+2.52%) ▲|USB58.58+0.44 (+0.75%) ▲|V326.67-0.57 (-0.17%) ▼|VZ45.41+0.04 (+0.09%) ▲|WFC83.81+1.61 (+1.95%) ▲|WMT117.20+0.02 (+0.02%) ▲|XOM138.48+0.67 (+0.49%) ▲|AAPL299.23+1.22 (+0.41%) ▲|ABBV229.90+13.41 (+6.19%) ▲|ABT88.22-0.19 (-0.21%) ▼|ACN119.17-8.82 (-6.89%) ▼|ADBE192.21-2.95 (-1.51%) ▼|AMAT622.55+5.44 (+0.88%) ▲|AMD545.39+8.02 (+1.49%) ▲|AMGN343.49+5.89 (+1.74%) ▲|AMT176.87+0.82 (+0.47%) ▲|AMZN234.41-9.99 (-4.09%) ▼|AVGO394.63-16.72 (-4.06%) ▼|AXP336.49-1.51 (-0.45%) ▼|BA220.85-1.87 (-0.84%) ▼|BAC57.32+1.12 (+1.98%) ▲|BKNG167.98-3.80 (-2.21%) ▼|BLK1,046.72-3.38 (-0.32%) ▼|BMY54.41+0.41 (+0.75%) ▲|BNY145.86+2.23 (+1.55%) ▲|BRK-B489.03-0.43 (-0.09%) ▼|C145.35+2.29 (+1.60%) ▲|CAT1,017.74+31.92 (+3.24%) ▲|CL89.69+0.21 (+0.23%) ▲|CMCSA22.40-0.04 (-0.16%) ▼|COF200.90-0.64 (-0.32%) ▼|COP109.38+1.64 (+1.52%) ▲|COST948.42-3.03 (-0.32%) ▼|CRM149.11-2.67 (-1.76%) ▼|CSCO121.19+1.65 (+1.38%) ▲|CVS101.85+3.53 (+3.59%) ▲|CVX175.00+1.37 (+0.79%) ▲|DE596.83+7.59 (+1.29%) ▲|DHR177.81+0.64 (+0.36%) ▲|DIS101.91-1.99 (-1.91%) ▼|DUK124.26+0.40 (+0.32%) ▲|EMR149.71-0.95 (-0.63%) ▼|FDX327.69+2.71 (+0.83%) ▲|GD343.06-6.95 (-1.99%) ▼|GE357.43-0.21 (-0.06%) ▼|GEV1,126.04+16.31 (+1.47%) ▲|GILD124.53+0.77 (+0.62%) ▲|GM80.88+1.59 (+2.01%) ▲|GOOG347.18-20.28 (-5.52%) ▼|GOOGL347.82-20.21 (-5.49%) ▼|GS1,098.72+2.16 (+0.20%) ▲|HD326.72-7.56 (-2.26%) ▼|HON228.36-0.66 (-0.29%) ▼|IBM246.50-2.60 (-1.04%) ▼|INTC140.81+6.82 (+5.09%) ▲|INTU256.53-10.47 (-3.92%) ▼|ISRG401.95-4.83 (-1.19%) ▼|JNJ230.40+2.01 (+0.88%) ▲|JPM331.90+6.68 (+2.05%) ▲|KO79.84+0.45 (+0.57%) ▲|LIN514.18+2.03 (+0.40%) ▲|LLY1,104.38+5.81 (+0.53%) ▲|LMT492.33-18.62 (-3.64%) ▼|LOW214.13-8.07 (-3.63%) ▼|LRCX395.18+6.14 (+1.58%) ▲|MA483.72-6.07 (-1.24%) ▼|MCD270.80-7.82 (-2.81%) ▼|MDLZ59.85-0.27 (-0.45%) ▼|MDT79.17-0.17 (-0.21%) ▼|META565.20-12.02 (-2.08%) ▼|MMM162.45+1.85 (+1.15%) ▲|MO69.65+0.53 (+0.76%) ▲|MRK114.75+0.88 (+0.77%) ▲|MS227.19+4.02 (+1.80%) ▲|MSFT370.13-9.27 (-2.44%) ▼|MU1,194.66+60.67 (+5.35%) ▲|NEE86.60-0.16 (-0.18%) ▼|NFLX72.86-4.52 (-5.84%) ▼|NKE43.21-2.00 (-4.41%) ▼|NOW92.05-2.99 (-3.15%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.26-9.04 (-4.90%) ▼|PEP140.70-1.33 (-0.93%) ▼|PFE25.01-0.21 (-0.81%) ▼|PG148.80-1.58 (-1.05%) ▼|PLTR119.62-8.86 (-6.89%) ▼|PM173.53-4.87 (-2.73%) ▼|QCOM222.21-3.90 (-1.72%) ▼|RTX182.46-3.14 (-1.69%) ▼|SBUX100.00-0.65 (-0.65%) ▼|SCHW92.03+0.33 (+0.35%) ▲|SO93.86+0.77 (+0.82%) ▲|SPG213.67+2.34 (+1.11%) ▲|T22.17+0.16 (+0.70%) ▲|TMO461.89-2.72 (-0.59%) ▼|TMUS181.05-0.62 (-0.34%) ▼|TSLA405.86+5.37 (+1.34%) ▲|TXN328.55+5.69 (+1.76%) ▲|UBER71.74+0.10 (+0.14%) ▲|UNH408.36+7.40 (+1.84%) ▲|UNP259.79+2.91 (+1.13%) ▲|UPS107.50+2.64 (+2.52%) ▲|USB58.58+0.44 (+0.75%) ▲|V326.67-0.57 (-0.17%) ▼|VZ45.41+0.04 (+0.09%) ▲|WFC83.81+1.61 (+1.95%) ▲|WMT117.20+0.02 (+0.02%) ▲|XOM138.48+0.67 (+0.49%) ▲|
22.6 C
New York
Monday, June 22, 2026

Tag: pharmaceutical

newssourceFORcompanyinformationcontent1marketreleases

Modified Cassava Starch Market worth $3.37 billion by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 23, 2025 /PRNewswire/ -- According to MarketsandMarkets™, The modified cassava starch market is projected to grow from USD 2.52 billion in...

Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening

Compounds developed through collaboration with Variational AI show targeted activity 
Compounds developed through collaboration with Variational AI show targeted activity

Ipsen announces changes to its Executive Committee

PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:

Tag along with Jay at CISCE: 3, 2, 1, Go! Linking you to a better lifestyle

BEIJING, July 22, 2025 /PRNewswire/ -- This is a report from China.org.cn: ...

HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000...

NEW YORK CITY and NEW ORLEANS, July 22, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased the Company’s securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.

XORTX Completes Non-Brokered Private Placement of Units

Not For Distribution to United States News Wire Services or for Dissemination in the United States

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025.

NEWBEAUTY RELEASES ‘THE STATE OF AESTHETICS: BY THE NUMBERS SUMMER 2025’

CRANBURY, N.J., July 22, 2025 /PRNewswire/ -- NewBeauty , the definitive authority on all things beauty, has announced the release of The State of Aesthetics: By the...

Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch

Veteran pharma operator co-founded Ategenos to tackle the global $1 trillion crisis of medication non-adherence CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Ategenos, a pharmatech...

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1...

Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

Basel, 22 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its Board of Directors' decision to propose to shareholders a modernisation of Roche Holding Ltd’s capital structure for approval at the Annual General Meeting to be held on 10 March 2026 ("2026 AGM"). The proposal includes the exchange of the existing non-voting equity securities (“Genussscheine”) for participation certificates with a nominal value of CHF 0.001 each.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceutical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers